asco@alo33:162242 JSONTXT

Background: Side effects are associated ith discontinuation of and non-adherence to aromatase inhibitor AI treatment among breast cancer patients. Musculoskeletal pain is a ell-documented side effect of AIs; hoever, there is a gap in knoledge regarding other side effects. The purpose of this study as to examine side effects, including those related to cognition and fatigue, associated ith AIs and to determine hether the side effects ere related to treatment discontinuation. Methods: Data ere analyzed from a cohort of 146 breast cancer patients initiating AI therapy and folloed for 1-year, and a cohort of 144 postmenopausal omen ithout a history of cancer folloed for 6-months. At baseline prior to AI therapy for breast cancer patients , and at 3-months, 6-months, and 1-year for breast cancer patients only , a comprehensive questionnaire as administered that ascertained data on symptoms, including forgetfulness, difficulty concentrating, fatigue, and problems ith vision and hearing. Odds ratios ORs and 95 percent confidence intervals 95 percent CIs adjusted for age, body mass index, and race ere calculated using logistic regression for ne onset of symptoms among the breast cancer patients compared to the omen ithout a history of cancer. Results: Among breast cancer patients mean age = 63y , 34.2 percent ere treated ith chemotherapy prior to AI treatment. Over the first 6 months of AI treatment, breast cancer patients had significantly higher odds of reporting ne onset of forgetfulness OR 4.0; 95 percent CI 1.7, 9.6 , difficulty concentrating OR 2.7; 95 percent CI 1.3; 5.8 , fatigue OR 4.1; 95 percent CI 1.1, 14.5 , and hair loss OR 4.1; 95 percent CI 1.9, 9.2 compared to the omen ithout a history of cancer. Similar increases in odds ere observed for the subgroup of omen not treated ith chemotherapy versus the comparison group. Further, among all breast cancer patients, the prevalence of hearing problems, hair loss, and forgetfulness increased significantly over the 1-year study period. Discontinuation rates ere higher, but not statistically significant, among those reporting these symptoms at 1-year. Conclusions: AI-related symptoms should be monitored and addressed so that adherence to therapy is maintained.,J Clin Oncol 34, 2016 suppl; abstr 10076 00:00.0,Patient and Survivor Care